Revolution Medicines Starts EU Review of Daraxonrasib
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22 hours ago
0mins
Revolution Medicines announced that European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has started a phased review of data on daraxonrasib, the company's investigational RAS multi-selective inhibitor. A phased review aims to accelerate the assessment of a medicine by evaluating the data in phases as they become available, ahead of the submission of a full marketing authorization application. Daraxonrasib was designated by the EMA as an orphan medicinal product for the treatment of pancreatic cancer and has been recognized as a high priority under EMA's Cancer Medicines Pathfinder project based on its potential to address a high unmet medical need. In addition, the company continues to make significant progress on its rolling submission of a new drug application for daraxonrasib to the FDA under the Commissioner's National Priority Voucher pilot program, which is intended to accelerate the development and review of therapies aligned with U.S. national health priorities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RVMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RVMD
Wall Street analysts forecast RVMD stock price to fall
20 Analyst Rating
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 189.990
Low
67.00
Averages
86.00
High
147.00
Current: 189.990
Low
67.00
Averages
86.00
High
147.00
About RVMD
Revolution Medicines, Inc. is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The Company's research and development pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The Company is advancing a pipeline of RAS(ON) Inhibitors, daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor are in clinical development. The Company's pipeline also focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). The Daraxonrasib, our RAS(ON) multi-selective inhibitor, is designed as an oral, tri-complex inhibitor of multiple RAS(ON) variants containing cancer driver mutations at all three of the major RAS mutation hotspot positions, G12, G13, and Q61.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
EMA Accelerates Review of Daraxonrasib for Pancreatic Cancer
- Clinical Trial Results: Daraxonrasib demonstrated significant survival improvements in the pivotal RASolute 302 trial, outperforming standard chemotherapy in overall survival and progression-free survival, indicating its potential to transform treatment paradigms for pancreatic cancer.
- EMA Review Process: The European Medicines Agency (EMA) has initiated a phased review of daraxonrasib, aiming to accelerate the assessment process, which not only highlights the drug's high priority but also underscores its importance in addressing the significant unmet medical needs of pancreatic cancer patients.
- NDA Submission Progress: The company is advancing its rolling New Drug Application (NDA) for daraxonrasib, nearing completion, which will expedite its market entry in the U.S. and enhance the company's competitive position in oncology treatment.
- Global Regulatory Engagement: Ongoing discussions with regulatory authorities worldwide as the company prepares for submissions in additional territories reflect its strategic intent to promote daraxonrasib globally, aiming to provide new therapies to patients as quickly as possible.
See More
EU Accelerates Review of Daraxonrasib for Pancreatic Cancer
- Accelerated Review: The European Medicines Agency has announced plans to expedite the review of Revolution Medicines' pancreatic cancer drug daraxonrasib, highlighting its significance in addressing patient needs as clinical data becomes available.
- Survival Rate Improvement: Recent clinical trial data indicates that daraxonrasib, as a late-line treatment option, nearly doubles survival rates for pancreatic cancer patients compared to traditional chemotherapy, demonstrating substantial therapeutic potential and meeting urgent market demand.
- Strong Market Demand: The EMA noted that treatment options for metastatic pancreatic cancer patients are extremely limited, with a life expectancy of only about six months, thus the introduction of daraxonrasib will fill a significant medical gap, carrying important market implications.
- Current U.S. Approval Status: Although daraxonrasib remains an investigational therapy, it has been approved for use in the U.S. under carefully controlled conditions, showcasing its potential in clinical applications and further enhancing Revolution Medicines' market outlook.
See More
Biotech Stocks Outperform S&P 500 in H1 2026
- Moderna's Recovery Potential: Moderna forecasts a revenue growth of up to 10% in 2026 and is awaiting regulatory approval for a new flu vaccine on August 5; despite expectations of a 40% price decline over the next 12 months, the launch of new products presents significant growth opportunities for the company.
- Breakthrough Cancer Drug: Revolution Medicines reported unprecedented survival rates for its cancer drug Daraxonrasib in phase 3 trials and plans to submit for regulatory review; while Wall Street anticipates only a 2% price increase in the coming months, the drug's potential market impact is substantial.
- Axsome's Growth Drivers: Axsome Therapeutics is expected to see a 13% price increase over the next year, driven by the approval of its drugs Auvelity and Symbravo, with ongoing phase 3 trials across five treatment areas that could lead to explosive earnings growth if successful.
- Market Sentiment Shift: Despite overall market pressures from turmoil in Iran and rising oil prices, biotech stocks have thrived as investors shift towards new opportunities, reflecting strong demand and confidence in innovative therapies.
See More
Biotech Companies Reach Critical Turning Point
- Moderna's Recovery Outlook: Moderna anticipates a revenue growth of up to 10% in 2026 and is awaiting potential approval for a flu vaccine on August 5, which could provide new growth momentum, although the market expects a 40% pullback in stock price over the next 12 months.
- Revolution Medicines Breakthrough: Revolution Medicines reported significant results in phase 3 trials for its cancer drug, daraxonrasib, showing a median survival of 13.2 months in previously treated metastatic pancreatic cancer, far exceeding chemotherapy's 6.7 months, with plans to submit for regulatory review, indicating substantial future growth potential.
- Axsome's Growth Potential: Axsome Therapeutics is expected to see a 13% stock price increase over the next 12 months, driven by its drugs Auvelity and Symbravo targeting agitation associated with Alzheimer's and migraines, respectively, while ongoing phase 3 trials could lead to explosive earnings growth if successful.
- Market Dynamics Analysis: Despite the S&P 500's over 9% gain in the first half of 2026, biotech companies like Moderna, Revolution Medicines, and Axsome outperformed, reflecting investor interest in emerging opportunities, which may shift market funds towards these high-potential stocks.
See More
Revolution Medicines Stock Soars 140% Amid Promising Trials
- Significant Stock Surge: Revolution Medicines' stock has surged nearly 140% in 2023, reflecting strong investor interest in its innovative oncology treatment technology, particularly following positive clinical trial results that indicate optimism about future revenue potential.
- Impressive Clinical Trial Results: In a phase 3 trial for metastatic pancreatic cancer, daraxonrasib achieved a survival rate of 13.2 months, significantly higher than the 6.7 months for standard chemotherapy, showcasing the drug's potential in treating hard-to-treat cancers and paving the way for a regulatory review request.
- Increased R&D Investment: Despite having no products on the market, the company's recent quarterly R&D loss has reached $453 million; however, its $1.9 billion cash position and $2.1 billion in net financing proceeds will support ongoing R&D efforts, demonstrating a long-term commitment to cancer treatment.
- Optimistic Commercial Outlook: With its lead candidate nearing market readiness, Revolution Medicines is poised for potential revenue growth, and regulatory approval could open new revenue streams, reducing investment risk and enhancing market competitiveness.
See More
Revolution Medicines Advances Cancer Treatment Approaches
- Significant R&D Progress: Revolution Medicines' lead product daraxonrasib demonstrated a survival rate of 13.2 months in phase 3 trials for metastatic pancreatic cancer, compared to 6.7 months for standard chemotherapy, indicating strong potential and supporting a regulatory review request.
- Innovative Technology Breakthrough: The company has developed 'druggable' RAS protein targets using its tri-complex inhibitor platform, addressing previously deemed 'undruggable' issues, which could open new avenues for cancer treatment and enhance market competitiveness.
- Robust Financial Position: Despite a doubling of R&D expenses to over $453 million in the recent quarter, the company maintains a cash reserve of $1.9 billion and $2.1 billion in net financing proceeds, demonstrating financial resilience during this high-risk investment phase.
- Increased Market Attention: Revolution Medicines' stock price has surged nearly 140% this year, reflecting investor optimism regarding its technological potential and future revenue, with the impending regulatory review suggesting a pathway to commercialization in the biotech sector, further boosting market confidence.
See More
EMA Accelerates Review of Daraxonrasib for Pancreatic Cancer
- Clinical Trial Results: Daraxonrasib demonstrated significant survival improvements in the pivotal RASolute 302 trial, outperforming standard chemotherapy in overall survival and progression-free survival, indicating its potential to transform treatment paradigms for pancreatic cancer.
- EMA Review Process: The European Medicines Agency (EMA) has initiated a phased review of daraxonrasib, aiming to accelerate the assessment process, which not only highlights the drug's high priority but also underscores its importance in addressing the significant unmet medical needs of pancreatic cancer patients.
- NDA Submission Progress: The company is advancing its rolling New Drug Application (NDA) for daraxonrasib, nearing completion, which will expedite its market entry in the U.S. and enhance the company's competitive position in oncology treatment.
- Global Regulatory Engagement: Ongoing discussions with regulatory authorities worldwide as the company prepares for submissions in additional territories reflect its strategic intent to promote daraxonrasib globally, aiming to provide new therapies to patients as quickly as possible.
See More
EU Accelerates Review of Daraxonrasib for Pancreatic Cancer
- Accelerated Review: The European Medicines Agency has announced plans to expedite the review of Revolution Medicines' pancreatic cancer drug daraxonrasib, highlighting its significance in addressing patient needs as clinical data becomes available.
- Survival Rate Improvement: Recent clinical trial data indicates that daraxonrasib, as a late-line treatment option, nearly doubles survival rates for pancreatic cancer patients compared to traditional chemotherapy, demonstrating substantial therapeutic potential and meeting urgent market demand.
- Strong Market Demand: The EMA noted that treatment options for metastatic pancreatic cancer patients are extremely limited, with a life expectancy of only about six months, thus the introduction of daraxonrasib will fill a significant medical gap, carrying important market implications.
- Current U.S. Approval Status: Although daraxonrasib remains an investigational therapy, it has been approved for use in the U.S. under carefully controlled conditions, showcasing its potential in clinical applications and further enhancing Revolution Medicines' market outlook.
See More
Biotech Stocks Outperform S&P 500 in H1 2026
- Moderna's Recovery Potential: Moderna forecasts a revenue growth of up to 10% in 2026 and is awaiting regulatory approval for a new flu vaccine on August 5; despite expectations of a 40% price decline over the next 12 months, the launch of new products presents significant growth opportunities for the company.
- Breakthrough Cancer Drug: Revolution Medicines reported unprecedented survival rates for its cancer drug Daraxonrasib in phase 3 trials and plans to submit for regulatory review; while Wall Street anticipates only a 2% price increase in the coming months, the drug's potential market impact is substantial.
- Axsome's Growth Drivers: Axsome Therapeutics is expected to see a 13% price increase over the next year, driven by the approval of its drugs Auvelity and Symbravo, with ongoing phase 3 trials across five treatment areas that could lead to explosive earnings growth if successful.
- Market Sentiment Shift: Despite overall market pressures from turmoil in Iran and rising oil prices, biotech stocks have thrived as investors shift towards new opportunities, reflecting strong demand and confidence in innovative therapies.
See More
Biotech Companies Reach Critical Turning Point
- Moderna's Recovery Outlook: Moderna anticipates a revenue growth of up to 10% in 2026 and is awaiting potential approval for a flu vaccine on August 5, which could provide new growth momentum, although the market expects a 40% pullback in stock price over the next 12 months.
- Revolution Medicines Breakthrough: Revolution Medicines reported significant results in phase 3 trials for its cancer drug, daraxonrasib, showing a median survival of 13.2 months in previously treated metastatic pancreatic cancer, far exceeding chemotherapy's 6.7 months, with plans to submit for regulatory review, indicating substantial future growth potential.
- Axsome's Growth Potential: Axsome Therapeutics is expected to see a 13% stock price increase over the next 12 months, driven by its drugs Auvelity and Symbravo targeting agitation associated with Alzheimer's and migraines, respectively, while ongoing phase 3 trials could lead to explosive earnings growth if successful.
- Market Dynamics Analysis: Despite the S&P 500's over 9% gain in the first half of 2026, biotech companies like Moderna, Revolution Medicines, and Axsome outperformed, reflecting investor interest in emerging opportunities, which may shift market funds towards these high-potential stocks.
See More
Revolution Medicines Stock Soars 140% Amid Promising Trials
- Significant Stock Surge: Revolution Medicines' stock has surged nearly 140% in 2023, reflecting strong investor interest in its innovative oncology treatment technology, particularly following positive clinical trial results that indicate optimism about future revenue potential.
- Impressive Clinical Trial Results: In a phase 3 trial for metastatic pancreatic cancer, daraxonrasib achieved a survival rate of 13.2 months, significantly higher than the 6.7 months for standard chemotherapy, showcasing the drug's potential in treating hard-to-treat cancers and paving the way for a regulatory review request.
- Increased R&D Investment: Despite having no products on the market, the company's recent quarterly R&D loss has reached $453 million; however, its $1.9 billion cash position and $2.1 billion in net financing proceeds will support ongoing R&D efforts, demonstrating a long-term commitment to cancer treatment.
- Optimistic Commercial Outlook: With its lead candidate nearing market readiness, Revolution Medicines is poised for potential revenue growth, and regulatory approval could open new revenue streams, reducing investment risk and enhancing market competitiveness.
See More
Revolution Medicines Advances Cancer Treatment Approaches
- Significant R&D Progress: Revolution Medicines' lead product daraxonrasib demonstrated a survival rate of 13.2 months in phase 3 trials for metastatic pancreatic cancer, compared to 6.7 months for standard chemotherapy, indicating strong potential and supporting a regulatory review request.
- Innovative Technology Breakthrough: The company has developed 'druggable' RAS protein targets using its tri-complex inhibitor platform, addressing previously deemed 'undruggable' issues, which could open new avenues for cancer treatment and enhance market competitiveness.
- Robust Financial Position: Despite a doubling of R&D expenses to over $453 million in the recent quarter, the company maintains a cash reserve of $1.9 billion and $2.1 billion in net financing proceeds, demonstrating financial resilience during this high-risk investment phase.
- Increased Market Attention: Revolution Medicines' stock price has surged nearly 140% this year, reflecting investor optimism regarding its technological potential and future revenue, with the impending regulatory review suggesting a pathway to commercialization in the biotech sector, further boosting market confidence.
See More
